Why the study?
Evidence comparing the efficacy and safety of potent P2Y12 inhibitors with clopidogrel is limited in patients with acute myocardial infarction complicated by cardiogenic shock.
Does the use of potent P2Y12 inhibitors reduce major adverse cardiovascular events compared with clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock?
Does the use of potent P2Y12 inhibitors reduce major adverse cardiovascular events compared with clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock?
In patients with acute myocardial infarction complicated by cardiogenic shock, potent P2Y12 inhibitors were associated with a lower risk of MACE compared to clopidogrel without an overall increase in major bleeding, though bleeding risk was elevated in the elderly and those on VA-ECMO.
Answers are grounded in this paper and cite their sources.
May support potent P2Y12 use except age ≥75 or VA-ECMO; leaves open randomized confirmation before practice change.
Although potent P2Y12 inhibitors, such as ticagrelor and prasugrel, are standard treatment in patients with acute myocardial infarction (AMI), evidence for their efficacy and safety compared with clopidogrel is limited in patients with AMI complicated by cardiogenic shock. Among 28,949 patients from the nationwide pooled registry of KAMIR-NIH and KAMIR-V, a total of 1482 patients (5.1%) with AMI and cardiogenic shock who underwent percutaneous coronary intervention of the culprit vessel were selected. Primary outcome was major adverse cardiovascular event (MACE, a composite of cardiac death, MI, repeat revascularization and definite stent thrombosis) and major secondary outcome was Bleeding Academic Research Consortium (BARC) type 2 or greater bleeding at 2 years. Among the study population, 537 patients (36.2%) received potent P2Y12 inhibitors and 945 patients (63.8%) received clopidogrel after index procedure. The risk of MACE was significantly lower in the potent P2Y12 inhibitors group than in the clopidogrel group (16.6% versus 24.7%; adjusted hazard ratio [HR], 0.76 [95% CI 0.59–0.99]; P = 0.046). Regarding BARC type 2 or greater bleeding, there was no significant difference between the potent P2Y12 inhibitors group and the clopidogrel group (12.5% versus 10.7%; adjusted HR, 1.36 [95% CI 0.98–1.88]; P = 0.064). Significant interaction was observed in patients aged ≥ 75 years (interaction P = 0.021) or venoarterial extracorporeal membrane oxygenator (VA-ECMO) use (interaction P = 0.015) for significantly increased risk of BARC type 2 or greater bleeding following the use of potent P2Y12 inhibitors. In patients with AMI complicated by cardiogenic shock, the use of potent P2Y12 inhibitors was associated with a lower risk of MACE compared with clopidogrel, without an increased risk of BARC type 2 or greater bleeding. The current data supports the use of potent P2Y12 inhibitors in patients with AMI and cardiogenic shock, except in patients aged ≥ 75 years or receiving VA-ECMO support.
No takes yet. Share an insight, caveat, or question.
Jo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: